Skip to main content

Day: March 28, 2022

Dimensional Fund Advisors Ltd. : Form 8.3 – GXO LOGISTICS INC – Ordinary Shares

FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1.        KEY INFORMATION(a)   Full name of discloser:   Dimensional Fund Advisors Ltd. (“Dimensional”), in its capacity as investment manager and on behalf its affiliates who are also investment managers. Dimensional and its affiliates expressly disclaim beneficial ownership of the shares described in this form 8.3(b)   Owner or controller of interests and short positions disclosed, if different from 1(a):        The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.    (c)   Name of offeror/offeree in relation to whose relevant securities this form relates:        Use a separate...

Continue reading

Checkpoint Therapeutics Reports Full-Year 2021 Financial Results and Recent Corporate Highlights

WALTHAM, Mass., March 28, 2022 (GLOBE NEWSWIRE) — Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the full-year ended December 31, 2021 and recent corporate highlights. James F. Oliviero, President and Chief Executive Officer of Checkpoint, said, “The past year represented a truly transformational period for Checkpoint Therapeutics, with the foundation laid for multiple significant potentially value enhancing catalysts in 2022. Following the positive topline results from our ongoing registrational trial of cosibelimab in metastatic cutaneous squamous cell carcinoma announced earlier this year, we look forward to a planned Biologics License Application submission for cosibelimab later in 2022.” Mr. Oliviero continued,...

Continue reading

BrainsWay Appoints Dr. Joachim Seidel as Vice President of Corporate Development and Strategy

Dr. Seidel has more than 20 years of experience in the medical device industry BURLINGTON, Mass. and JERUSALEM, March 28, 2022 (GLOBE NEWSWIRE) — BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the appointment of Joachim “Joe” Seidel, Ph.D., to the newly created position of Vice President of Corporate Development and Strategy. Dr. Seidel has more than 20 years of experience in the medical device industry and has held positions in business development, corporate strategy, program management, and research and development. He will be responsible for pursuing strategic opportunities for BrainsWay and overseeing its global corporate development initiatives. “Joe brings a unique breadth of experience...

Continue reading

Decisions taken by Enento Group Plc’s Annual General Meeting and Board of Directors

ENENTO GROUP PLC, STOCK EXCHANGE RELEASE 28 MARCH 2022, 3:00 P.M. EEST Decisions taken by Enento Group Plc’s Annual General Meeting and Board of Directors The Annual General Meeting of Enento Group Plc was held today at the headquarters of the company in Helsinki, Finland under special arrangements due to the Covid-19 pandemic. 82 shareholders representing 17 474 412 shares and votes were represented at the meeting. The Annual General Meeting approved the Financial Statements and discharged the members of the Board of Directors and the company’s CEO from liability for the financial year 2021 and resolved to approve the Remuneration report for governing bodies. The Annual General Meeting approved the Board of Directors’ proposal to distribute funds of EUR 1.00 per share as an equity repayment from the reserve for invested unrestricted...

Continue reading

ME2C Environmental Exercises Right of First Refusal with Major U.S. Utility, Patented Mercury Emissions Technology Licensee, to Supply Product Valued at $1 Million Annually

ME2C to Supply Its Custom Sorbents; Increasing the Company’s Momentum Across U.S. Coal-Fired Market Corsicana, TX, March 28, 2022 (GLOBE NEWSWIRE) — Midwest Energy Emissions Corp. (OTCQB: MEEC) (“ME2C Environmental ” or the “Company”), a leading environmental technologies firm, announced today that it has exercised its right of first refusal (“ROFR”) for mercury emissions capture product supply with a significant coal-powered utility operating in the Midwest. This major utility entered into a license agreement with the Company in 2021 which agreement provided a ROFR with respect to certain future supply business. ME2C Environmental is exercising the ROFR and matching the terms of an offer made by another supplier for a direct three-year supply order and a renewal option, which is expected to have a value...

Continue reading

Sunrun Announces Date and Conference Call Details for First Quarter 2022 Earnings Report

Earnings Release and Conference Call Scheduled for May 4, 2022 SAN FRANCISCO, March 28, 2022 (GLOBE NEWSWIRE) — Sunrun (Nasdaq: RUN) today announced that it will issue its first quarter 2022 earnings report after the market closes on Wednesday, May 4, 2022. A conference call has been scheduled to discuss these earnings results at 1:30 p.m. Pacific Time. The conference call can be accessed live via the Sunrun Investor Relations website at https://investors.sunrun.com or over the phone by dialing (877) 407-5989 (toll-free) or (201) 689-8434 (toll). An audio replay will be available following the call on the Sunrun Investor Relations website for approximately one month. About Sunrun                                     Sunrun Inc. (Nasdaq: RUN) is the nation’s leading home solar, battery storage, and energy services company. Founded...

Continue reading

Oncocyte to Present New Data Confirming Association of IO Score with Response to Immunotherapy Treatment for Bladder Cancer at the American Association for Cancer Research Annual Meeting 2022

Poster outlines data showing Oncocyte’s DetermaIO™ tool can inform therapeutic decisions and has the potential to improve outcomes for patients with bladder cancer IRVINE, Calif., March 28, 2022 (GLOBE NEWSWIRE) — Oncocyte Corporation (Nasdaq: OCX), a precision diagnostics company with the mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey, today announced that it will present new confirmatory data on DetermaIO™, its 27-gene expression test used to identify responders to immune checkpoint inhibitor (ICI) therapies, at the American Association for Cancer Research (AACR) Annual Meeting 2022, taking place April 8-13, 2022 in New Orleans. The analysis in the poster builds on previous data, which showed that IO Score correlates with response to Genentech’s...

Continue reading

BIGG Digital Assets Inc. Subsidiary Netcoins Launches New Digital Assets: SHIB, DOGE, MATIC, FTM, and MANA

VANCOUVER British Columbia, March 28, 2022 (GLOBE NEWSWIRE) — BIGG Digital Assets Inc. (“BIGG” or the “Company”) (CSE: BIGG; OTCQX: BBKCF; WKN: A2PS9W), owner of Netcoins (Netcoins.ca) (“Netcoins”), the online cryptocurrency brokerage that makes it easy for Canadians to buy, sell, and understand cryptocurrency, is pleased to announce the launch of 5 new coins on the platform: SHIB, DOGE, MATIC, FTM and MANA. On March 24th, Netcoins received approval for an update to its restricted dealer license, which was requested in late 2021, enabling a broader offering of coins on the platform. These 5 coins represent the first rollout of our upcoming coin additions, with multiple rollouts expected to follow. Information on SHIB, DOGE, MATIC, FTM, and MANA can be found on coinmarketcap.com at the links below: https://coinmarketcap.com/currencies/shiba-inu/...

Continue reading

Enservco Corporation Reduces Debt and Strengthens Balance Sheet

DENVER, March 28, 2022 (GLOBE NEWSWIRE) — Enservco Corporation (NYSE American: ENSV), a diversified national provider of specialized well-site services to the domestic onshore conventional and unconventional oil and gas industries, today announced it has retired its $13.8 million senior revolving credit facility with East West Bank for total consideration of approximately $9.4 million, which includes an initial payment of $8.4 million in cash and future payments of up to $1.0 million from a limited portion of net proceeds from receivables financing. As a result of the refinancing, Enservco’s debt was substantially reduced and predominantly reclassified as long-term liabilities with four- to six-year terms. Equally important, the refinancing will have minimal impact on aggregate monthly debt and lease obligations, thus substantially...

Continue reading

ORYZON Announces Appointment of Douglas V. Faller, MD, PhD as Global Chief Medical Officer and Continues its Expansion of US Corporate Activities

Extensive academic and industry experience in hematology/oncology Will coordinate Oryzon’s global clinical development from Boston, USAMADRID, Spain and CAMBRIDGE, Mass., March 28, 2022 (GLOBE NEWSWIRE) — Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a public clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today the appointment of Douglas Faller, M.D., Ph.D., to the role of Global Chief Medical Officer. Dr. Faller has over 30 years of clinical hematology/oncology expertise and broad drug development experience in the design and execution of early to registrational clinical programs across oncology and rare diseases and will lead Oryzon’s global clinical development strategy. Based in Boston, Dr. Faller will strengthen Oryzon’s...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.